Clinical Trial Update: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lenvatinib plus pembrolizumab and chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma; results were posted on 2025-11-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Adenocarcinoma

Drugs mentioned

• Chemotherapy (unspecified regimen)
• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced/Metastatic Gastroesophageal Adenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-28